Characteristics of included studies in systematic review and meta-analysis
| First author | Trial name/cohort name | Year | No. of patients with metastatic UC | Immune checkpoint blockade treatment | Median follow-up time (months) | Method for FGFR3 mutation | Survival outcomes (HR (95% CI)) | Pathological responses | ||
| FGFR3-mutated | FGFR3-wildtype | FGFR3-mutated | FGFR3-wildtype | |||||||
| Wang et al24 | CheckMate275 | 2019 | 15 | 124 | Nivo | 7.0 | DNA sequencing | OS: 1.84 (0.96 to 3.51) | CR: 1 PR: 2 SD: 1 PD: 10 | CR: 9 PR: 17 SD: 27 PD: 51 |
| Wang et al24 | IMVigor210 | 2019 | 49 | 225 | Atezo | 11.7 | DNA sequencing | OS: 1.27 (0.84 to 1.92) | CR: 1 PR: 11 SD: 7 PD: 25 | CR: 20 PR: 28 SD: 37 PD: 108 |
| Samstein et al36 | MSKCC cohort (mBC) | 2019 | 29 | 118 | Atezo/Ave/Durva/ Nivo/Pembro/Ipi/Treme | 8.0 | DNA sequencing | OS: 1.25 (0.71 to 2.20) | – | – |
| Samstein et al36 | MSKCC cohort (mUTUC and mUUC) | 2019 | 12 | 40 | Atezo/Ave/Durva/ Nivo/Pembro/Ipi/Treme | 8.0 | DNA sequencing | OS: 1.06 (0.38 to 2.94) | – | – |
| Szabados et al35 | Clinico-Genomic Database | 2022 | 13 | 32 | Atezo/Durva/Nivo/Pembro | 9.4 | DNA sequencing | OS: 1.20 (0.71 to 2.03) | – | – |
| Rose et al31 | – | 2021 | 17 | 86 | Atezo/Ave/Durva/ Nivo/Pembro | 8.8 | DNA sequencing | OS: 1.39 (0.71 to 2.71) PFS: 1.46 (0.90 to 2.39) | CR: 1 PR: 1 SD: 2 PD: 13 | CR: 7 PR: 9 SD: 9 PD: 61 |
| Chawla et al38 | – | 2022 | 23 | 90 | Atezo/Durva/Nivo/Pembro/Ipi/Treme/Sparta/Lerami | 14.6 | DNA sequencing | OS: 1.13 (0.66 to 1.91) PFS: 1.54 (0.94 to 2.51) | – | – |
| Tully et al37 | – | 2021 | 11 | 54 | Nivo/Pembro/Atezo | 7.8 | RT-PCR | DSS: 5.42 (0.71 to 41.61) | – | – |
Atezo, atezolizumab; Ave, avelumab; CR, complete response; DSS, disease specific survival; Durva, durvalumab; HR, hazard ratio; Ipi, ipilimumab; Lerami, leramilimab; mBC, metastatic bladder cancer; MSKCC, Memorial Sloan Kettering Cancer Center; mUTUC, metastatic upper tract urothelial carcinoma; mUUC, metastatic urethral urothelial carcinoma; Nivo, nivolumab; OS, overall survival; PD, progressive disease; Pembro, pembrolizumab; PFS, progression-free survival; PR, partial response; RT-PCR, reverse transcription-PCR; SD, stable disease; Sparta, spartalizumab; Treme, tremelimumab.